Entities / Company
Exact Sciences.
American company in Madison, United States
- Reports this week
- 0
- Active events
- 1
- Connections
- 76
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
One to three months ago
-
Abbott Laboratories acquired Exact Sciences, a company specializing in cancer diagnostics, in a move that also involved competition in the medical device market.Well supported9 reports
-
Havas Edge headquarters are in San Diego, and the company works with Exact Sciences products. Pam Caputo is based in a Boston office.Some support1 report
Gone quiet
No new reports in 90+ days-
Competitors are impacted by market consolidation as a governing body oversees corporate strategic direction for Exact Sciences and Align Technology.Some support1 report
-
Dexcom, Roche, and Exact Sciences were cited as industry leaders innovating aggressively in POC solutions.Some support1 report
-
CMS granted Medicare coverage for Exact Sciences' Oncodetect test on July 9, 2025.Speculative1 report
-
William Blair analyst questioned the strategic fit of Freenome's partnership.Some support2 reports
-
Exact Sciences noted to potentially benefit from Trump-era tariffs and onshoring trends.Speculative1 report
-
Exact Sciences could benefit from Trump-era tariffs, with Jefferies reiterating a Buy rating on the company.Some support1 report
-
Broad Institute validates a new test for colorectal cancer recurrence monitoring, alongside reports that tariffs benefit AI stocks.Speculative1 report
-
Baird and Wells Fargo questioned Exact Sciences regarding revenue guidance drivers, sales expenses, and blood-based screening data timelines.Speculative1 report
-
Exact Sciences developed the Oncodetect test on July 9, 2025.Speculative1 report
-
Exact Sciences and Qiagen are considered value stocks in the sector as of July 10, 2025.Some support1 report
-
Exact Sciences established its headquarters in Madison, Wisconsin on July 14, 2025.Some support2 reports
-
Wall Street analysts set price targets and positive earnings estimate revisions for Exact Sciences, suggesting potential stock upside.Some support1 report
-
Both Exact Sciences and Zoetis reported positive Earnings ESP on July 18, 2025.Some support1 report
-
Exact Sciences and Novartis both reported positive Earnings ESP on July 24, 2025.Some support1 report
-
Karl Stubelis was appointed CFO to oversee financial strategy, having previously held senior roles at Exact Sciences, Thrive, and Athenahealth.Some support1 report
-
Exact Sciences stock underperformed S&P 500 growth on July 25, 2025.Some support1 report
-
Exact Sciences' Cologuard Plus received FDA approval and expanded access for CRC screening in partnership with Humana and Mayo Clinic.Some support2 reports
-
Exact Sciences announced on August 8, 2025, that its revenue growth forecast is lower than the industry average.Some support2 reports
-
Exact Sciences acquired exclusive rights in the US and received a premarket application to the FDA from Freenome, alongside publishing study findings in JAMA.Well supported4 reports
-
Cathie Wood and Ark Invest increased their holdings in The Trade Desk, while Wood also bought more stock in Exact Sciences, amidst market volatility.Some support1 report
-
Agendia and Exact Sciences compete in genomic testing for breast cancer, with Agendia using LinkedIn for social media posts.Some support1 report
-
Exact Sciences withdrew an injunction against Geneoscopy's stool-based screening test, ColoSense.Some support1 report
-
Exact Sciences and DigitalBridge are involved in developing and marketing cancer screening tests, while also managing assets across data centers and fiber networks.Some support2 reports
-
Exact Sciences and Regeneron Pharmaceuticals operate within the immuno-oncology industry.Some support2 reports
-
RBC Capital Markets raised the price target for Exact Sciences stock on September 5, 2025.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Exact Sciences this week
News at the entities that move Exact Sciences most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves Exact Sciences
-
RBC Capital Markets Mentioned togetherFinancial institutions like RBC and Macquarie maintained 'outperform' ratings amid dashed hopes for a Strait of Hormuz reopening.Moves Exact Sciences
-
Align Technology OperationalDentsply Sirona and Align Technology are navigating industry-wide soft demand for dental equipment.Moves Exact Sciences
-
Mayo Clinic OperationalMayo Clinic researchers presented findings at the ASTRO meeting in Boston.Moves Exact Sciences
-
Humana OperationalHarley-Davidson, Humana, and Lloyds Banking Group were listed on major stock exchanges today.Moves Exact Sciences
-
Abbott Laboratories StructuralMarketBeat listed Abbott, Eli Lilly, Pfizer, Gilead, AbbVie, and McKesson as stocks to watch on June 7, 2026.Moves Exact Sciences
Connections
The 9 strongest of 76, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Abbott Laboratories Structural
Abbott Laboratories acquired Exact Sciences, which is now fully integrated as a subsidiary.
-
Freenome (United States) Structural
Exact Sciences acquired US rights for Freenome's test, establishing an exclusive license agreement for commercialization.
-
FDA Structural
FDA regulates the approval process for Exact Sciences' medical products.
-
Align Technology Operational
The two companies are active competitors whose market pressures are influenced by broader industry consolidation trends.
-
Havas Structural
Exact Sciences products are utilized by clients of the marketing agency Havas, establishing a functional supply chain link.
-
Mayo Clinic Operational
Mayo Clinic and Exact Sciences are collaborating in partnership to develop Cologuard tests.
-
Dodge County Operational
Exact Sciences actively partners with Dodge County to support local health programs.
-
Humana Operational
The two companies have formed a partnership to expand access to CRC screening tests.
Show all 9 connections
-
RBC Capital Markets Mentioned together
RBC Capital Markets provides financial analysis and raises price targets for Exact Sciences stock.
History
Events by the month they beganJuly 2026
2 eventsJune 2026
26 events- Zacks Investment Research provided stock analysis and ratings for Exact Sciences.
- Competitors are impacted by market consolidation as a governing body oversees corporate strategic direction for Exact Sciences and Align Technology.
- Dexcom, Roche, and Exact Sciences were cited as industry leaders innovating aggressively in POC solutions.
- CMS granted Medicare coverage for Exact Sciences' Oncodetect test on July 9, 2025.
- William Blair analyst questioned the strategic fit of Freenome's partnership.
- Exact Sciences noted to potentially benefit from Trump-era tariffs and onshoring trends.
- Exact Sciences could benefit from Trump-era tariffs, with Jefferies reiterating a Buy rating on the company.
- Broad Institute validates a new test for colorectal cancer recurrence monitoring, alongside reports that tariffs benefit AI stocks.
- Baird and Wells Fargo questioned Exact Sciences regarding revenue guidance drivers, sales expenses, and blood-based screening data timelines.
- Exact Sciences developed the Oncodetect test on July 9, 2025.
- Exact Sciences and Qiagen are considered value stocks in the sector as of July 10, 2025.
- Exact Sciences established its headquarters in Madison, Wisconsin on July 14, 2025.
- Wall Street analysts set price targets and positive earnings estimate revisions for Exact Sciences, suggesting potential stock upside.
- Both Exact Sciences and Zoetis reported positive Earnings ESP on July 18, 2025.
- Exact Sciences and Novartis both reported positive Earnings ESP on July 24, 2025.
- Karl Stubelis was appointed CFO to oversee financial strategy, having previously held senior roles at Exact Sciences, Thrive, and Athenahealth.
- Exact Sciences stock underperformed S&P 500 growth on July 25, 2025.
- Exact Sciences' Cologuard Plus received FDA approval and expanded access for CRC screening in partnership with Humana and Mayo Clinic.
- Exact Sciences announced on August 8, 2025, that its revenue growth forecast is lower than the industry average.
- Exact Sciences acquired exclusive rights in the US and received a premarket application to the FDA from Freenome, alongside publishing study findings in JAMA.
- Cathie Wood and Ark Invest increased their holdings in The Trade Desk, while Wood also bought more stock in Exact Sciences, amidst market volatility.
- Agendia and Exact Sciences compete in genomic testing for breast cancer, with Agendia using LinkedIn for social media posts.
- Exact Sciences withdrew an injunction against Geneoscopy's stool-based screening test, ColoSense.
- Exact Sciences and DigitalBridge are involved in developing and marketing cancer screening tests, while also managing assets across data centers and fiber networks.
- Exact Sciences and Regeneron Pharmaceuticals operate within the immuno-oncology industry.
- RBC Capital Markets raised the price target for Exact Sciences stock on September 5, 2025.